The chemical class known as β'-COP inhibitors comprises a diverse group of organic compounds that share a common aim: the modulation of the activity of β'-COP, a critical component of the COPI (coatomer protein complex I) machinery involved in intracellular vesicle trafficking and protein transport. These inhibitors are designed with precision to perturb the function of β'-COP and, consequently, the processes governed by the COPI complex. β'-COP is pivotal in the formation of vesicles that facilitate the transport of proteins within cells, contributing to the maintenance of cellular compartments and organelles. The uniqueness of the β'-COP inhibitors class stems from their specific chemical structures, which are strategically designed to interact with β'-COP or its associated molecules. By interfering with β'-COP's function, these inhibitors disrupt vesicle formation, which impacts the trafficking of proteins within cells. This inhibition often occurs through the modulation of molecules such as ADP-ribosylation factor 1 (ARF1) and Golgi-specific Brefeldin A resistance factor 1 (GBF1), both of which are intricately involved in COPI vesicle assembly and protein transport processes.
Researchers employ β'-COP inhibitors as valuable tools to investigate the cellular consequences of inhibiting COPI vesicle formation. Through the alteration of vesicular trafficking patterns, these inhibitors enable the examination of the impacts on organelle integrity, intercellular communication, and protein compartmentalization. The chemical class of β'-COP inhibitors has been instrumental in unraveling the intricacies of cellular transport processes, facilitating a deeper understanding of the role of COPI-mediated trafficking in cellular function. By unraveling the complexities of these processes, researchers gain insights into the fundamental mechanisms underlying cellular organization and compartmentalization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
A naturally occurring compound that disrupts COPI vesicle formation by inhibiting ADP-ribosylation factor 1 (ARF1), which is involved in vesicle budding. This disruption affects β'-cop function. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
A synthetic compound that inhibits the exchange factor GBF1 (Golgi-specific Brefeldin A resistance factor 1), leading to the inhibition of COPI vesicle formation and β'-cop-mediated transport. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
A compound that selectively inhibits the binding of β'-cop to membranes, thus interfering with COPI vesicle formation and subsequent protein trafficking. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
A molecule that disrupts COPI vesicle formation by inhibiting ARF1 activation. This inhibition affects β'-cop function and protein transport. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
A mycotoxin that indirectly affects COPI vesicle formation by disturbing calcium homeostasis, leading to ER stress and potentially impacting β'-cop-mediated processes. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
This compound inhibits GBF1 activity, resulting in the disruption of COPI vesicle formation and interfering with β'-cop-mediated vesicle trafficking. | ||||||
Aurintricarboxylic Acid | 4431-00-9 | sc-3525 sc-3525A sc-3525B sc-3525C | 100 mg 1 g 5 g 10 g | $20.00 $32.00 $48.00 $94.00 | 13 | |
While mainly recognized for its ability to inhibit nucleic acid-protein interactions, this compound can also interfere with COPI vesicle formation and β'-cop functions. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Similar to Exo2, Exo1 disrupts COPI vesicle formation by inhibiting ARF1 activation, subsequently affecting β'-cop functions and protein transport. | ||||||
CGP 37157 | 75450-34-9 | sc-202097 sc-202097A | 5 mg 25 mg | $115.00 $463.00 | 3 | |
Although primarily recognized as a mitochondrial sodium/calcium exchanger inhibitor, CGP-37157 also impacts COPI vesicle formation and β'-cop functions through its effects on calcium homeostasis. | ||||||